Skip to main content

Amivantamab use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Aug 10, 2022.

Drugs containing Amivantamab: Rybrevant

Amivantamab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of amivantamab during breastfeeding. Because amivantamab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. The manufacturer recommends avoiding breastfeeding during amivantamab use and for 3 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

amivantamab

CAS Registry Number

2171511-58-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents, Immunological

Antibodies, Bispecific

Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.